OncoMed Pharmaceuticals, Inc. Logo
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
June 05, 2016 09:00 ET | OncoMed Pharmaceuticals, Inc.
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 ...
VBL Therapeutics.jpg
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
June 03, 2016 16:02 ET | VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...
Stemline logo
Stemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow
June 03, 2016 07:06 ET | Stemline Therapeutics, Inc.
NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN)...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
April 21, 2016 16:26 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American...
Provista Diagnostics
Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts
September 29, 2015 15:52 ET | Provista Diagnostics, Inc.
NEW YORK, NY, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc.  today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel...
Provista Diagnostics
Provista Diagnostics, Inc. published Late-Breaking Publication only Abstract in conjunction with the 2015 ASCO Annual Meeting
June 03, 2015 15:31 ET | Provista Diagnostics, Inc.
NEW YORK, NY, June 3, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc. today announced that they published an Abstract, in conjunction with the 2015 ASCO Annual Meeting held May 29 - June 2th, 2015...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
June 01, 2015 09:00 ET | OncoMed Pharmaceuticals, Inc.
Demcizumab plus Abraxane and Gemcitabine in Advanced Pancreatic Cancer Results in 50% Response Rate, Progression-Free Survival of 9.0 Months and Overall Survival of 10.1 Months Randomized Phase 2...
Chinook_yahoo_711x400.jpg
Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma
June 01, 2015 09:00 ET | Chinook Therapeutics, Inc.
BERKELEY, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of interim safety and efficacy data from an ongoing Phase 1b clinical trial of its...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed to Present at Upcoming Investment Conferences
May 28, 2015 16:30 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed to Present Data From Three Clinical Studies at the 2014 ASCO Annual Meeting
May 14, 2014 17:02 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...